SCR-LIP-000585 · Claim · machine-readable JSON →
Limited evidence suggests lipedema may be accompanied by lower rates of metabolic comorbidity than in women of similar age in the general population.
General proposition consolidated from 1 earlier single-paper claims; each study's own result is shown as its finding.
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- low (GRADE)
- Evidence
- 1 source(s)
- Answers
- 1 question(s)
- Dates
- 2026-11-20 → 2026-11-20
Structured evidence, machine-compiled — not a verdict.
Evidence over time
Evidence (1)
- Lipedema: friend and foe — Torre et al. (2018) ✓ verified — consistent · case series · 2018 · reading confidence: moderate
“Perfil cardiometabólico PROTETOR apesar de IMC obeso médio 35,3±1,7 kg/m²: diabetes apenas 2% (vs. ~10% mulheres NHANES idade-pareada); dislipidemia 11,7% (vs. 33,5%); hipertensão 13% (vs. 32,4% mulheres 40-59 anos)”
In 46 women with lipedema (mean BMI 35.3), diabetes 2% vs about 10% in age-matched NHANES women, dyslipidemia 11.7% vs 33.5%, hypertension 13% vs 32.4%; fat not reduced by lifestyle change.
The article describes lipedema as a distinct disorder frequently misdiagnosed as obesity or lymphedema, with characteristic fat distribution, staging, inheritance pattern, and a metabolic profile differing from obesity; supports the affirma
Context (PECO)
Answers these questions
Gaps & caveats
Change log
- 2026-11-20 — created_by_consolidation · general proposition consolidated from SQ-LIP-000001